Orion and US university partner up against cancer
Finnish pharmaceutical and diagnostics company Orion has announced a collaboration with a US non-profit organisation in pursuit of new medicines for oncological diseases.
Orion will start co-operating with The Wisconsin Technology Innovation Initiative (Wi2), a non-profit organisation formed to support the School of Medicine and Public Health at the University of Wisconsin-Madison.
The agreement means that target proteins identified and initially validated at UW-Madison will be provided to Orion as the first step in establishing a research and development collaboration. The research and development projects will be planned and conducted jointly.
“We are excited about partnering with Wi2 and the University of Wisconsin-Madison, which is recognised for its scientific excellence in the field of oncology,” says Reijo Salonen, senior vice president, pharmaceutical research and development and chief medical officer at Orion. “The university is performing fundamental research and also has excellent capabilities for Phase IIA clinical studies. These competence areas added to our expertise to develop a molecule to medicine are offering us a great opportunity to find, research and develop new treatments for patients suffering from oncological diseases.”
Wi2 is a private, non-profit corporation committed to cultivating and supporting innovation by researchers at the UW School of Medicine and Public Health at the University of Wisconsin-Madison.